Premium
Monocyte HLA‐DR Measurement by Flow Cytometry in COVID ‐19 Patients: An Interim Review
Author(s) -
Benlyamani Ihsane,
Venet Fabienne,
Coudereau Rémy,
Gossez Morgane,
Monneret Guillaume
Publication year - 2020
Publication title -
cytometry part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.316
H-Index - 90
eISSN - 1552-4930
pISSN - 1552-4922
DOI - 10.1002/cyto.a.24249
Subject(s) - immunosuppression , flow cytometry , immunology , hla dr , immune system , medicine , monocyte , sepsis , interim , covid-19 , antigen , disease , archaeology , infectious disease (medical specialty) , history
Several months after the sudden emergence of SARS‐CoV‐2 and COVID‐19, the understanding of the appropriate host immune response to a virus totally unknown of human immune surveillance is still of major importance. By international definition, COVID‐19 falls in the scope of septic syndromes (organ dysfunction due to dysregulated host response to an infection) in which immunosuppression is a significant driver of mortality. Sepsis‐induced immunosuppression is mostly defined and monitored by the measurement of decreased expression of HLA‐DR molecules on circulating monocytes (mHLA‐DR). In this interim review, we summarize the first mHLA‐DR results in COVID‐19 patients. In critically ill patients, results homogenously indicate a decreased mHLA‐DR expression, which, along with profound lymphopenia and other functional alterations, is indicative of a status of immunosuppression. © 2020 International Society for Advancement of Cytometry